Is Aligos Therapeutics, Inc. (ALGS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 19.5% / 30% | 132.6% / 30% | 0.0% / 30% | 1169.38% / 5% | ✗ NOT HALAL |
| DJIM | 19.5% / 33% | 132.6% / 33% | 0.0% / 33% | 1169.38% / 5% | ✗ NOT HALAL |
| MSCI | 11.9% / 33% | 81.2% / 33% | 0.0% / 33% | 1169.38% / 5% | ✗ NOT HALAL |
| S&P | 19.5% / 33% | 132.6% / 33% | 0.0% / 33% | 1169.38% / 5% | ✗ NOT HALAL |
| FTSE | 11.9% / 33% | 81.2% / 33% | 0.0% / 50% | 1169.38% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -12907.7% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -196.9% | |
| Return on Assets (ROA) | -69.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$83M |
| Free Cash Flow | -$83M |
| Total Debt | $5M |
| Debt-to-Equity | 9.8 |
| Current Ratio | 3.9 |
| Total Assets | $89M |
Price & Trading
| Last Close | $7.04 |
| 50-Day MA | $7.33 |
| 200-Day MA | $8.69 |
| Avg Volume | 56K |
| Beta | 2.8 |
|
52-Week Range
$3.76
| |
About Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Aligos Therapeutics, Inc. (ALGS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Aligos Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Aligos Therapeutics, Inc.'s debt ratio?
Aligos Therapeutics, Inc.'s debt ratio is 19.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 11.9%.
What are Aligos Therapeutics, Inc.'s key financial metrics?
Aligos Therapeutics, Inc. has a market capitalization of $41M, and revenue of $2M. Return on equity stands at -196.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.